Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Añadir filtros








Intervalo de año
1.
An. bras. dermatol ; 98(4): 429-439, July-Aug. 2023. tab, graf
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1447226

RESUMEN

Abstract The frequency of the use of drugs that act on the epidermal growth factor receptor (EGFR) is increasing, with the consequent onset of cutaneous toxicity, specifically acneiform eruption. The authors extensively review the topic, focusing on describing how these drugs can affect the skin and its appendages, that is, the pathophysiology that encompasses the cutaneous toxicity related to the use of EGFR inhibitors. In addition, it was possible to list the risk factors that may be associated with adverse effects of these drugs. Based on this recent knowledge, the authors expect to aid in the management of patients who are more vulnerable to toxicity, reduce morbidities, and improve the quality of life of patients undergoing treatment with EGFR inhibitors. Other issues related to the toxicity of EGFR inhibitors, such as the clinical aspects of the acneiform eruption grades, and other different types of cutaneous and mucosal reactions, are also included in the article.

3.
An. bras. dermatol ; 95(2): 133-143, Mar.-Apr. 2020. tab
Artículo en Inglés | LILACS, ColecionaSUS | ID: biblio-1130860

RESUMEN

Abstract Patients with psychocutaneous disorders often refuse psychiatric intervention in their first consultations, leaving initial management to the dermatologist. The use of psychotropic agents in dermatological practice, represented by antidepressants, antipsychotics, anxiolytics, and mood stabilizers, should be indicated so that patients receive the most suitable treatment rapidly. It is important for dermatologists to be familiar with the most commonly used drugs for the best management of psychiatric symptoms associated with dermatoses, as well as to manage dermatologic symptoms triggered by psychiatric disorders.


Asunto(s)
Humanos , Masculino , Femenino , Trastornos Psicofisiológicos/tratamiento farmacológico , Psicotrópicos/uso terapéutico , Enfermedades de la Piel/psicología , Enfermedades de la Piel/tratamiento farmacológico , Trastornos Mentales/tratamiento farmacológico , Factores de Riesgo , Dermatología
5.
An. bras. dermatol ; 89(1): 26-36, Jan-Feb/2014. tab, graf
Artículo en Inglés | LILACS | ID: lil-703556

RESUMEN

Incontinentia pigmenti is a rare genodermatosis in which the skin involvement occurs in all patients. Additionally, other ectodermal tissues may be affected, such as the central nervous system, eyes, hair, nails and teeth. The disease has a X-linked dominant inheritance pattern and is usually lethal to male fetuses. The dermatological findings occur in four successive phases, following the lines of Blaschko: First phase - vesicles on an erythematous base; second phase - verrucous hyperkeratotic lesions; third phase - hyperchromic spots and fourth phase - hypochromic atrophic lesions.


Asunto(s)
Humanos , Masculino , Piel/patología , Incontinencia Pigmentaria/patología , Anomalías Dentarias/etiología , Anomalías Dentarias/patología , Catarata/etiología , Catarata/patología , Incontinencia Pigmentaria/complicaciones , Enfermedades del Sistema Nervioso Central/patología , Alopecia/etiología , Alopecia/patología , Mutación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA